AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10474558 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (no program until after the follow-up survey)
Number of subjects: 2519
Study 8743353 — intervention group
Group type: COMPARATOR
Intervention: Microsurgical epididymal sperm aspiration (MESA) with ICSI; 29 cycles performed on 25 couples.
Number of subjects: 53
Study 8743353 — intervention group
Group type: EXPERIMENTAL
Intervention: Epididymal micropuncture with nerve stimulation with ICSI; 30 cycles performed on 28 couples.
Number of subjects: 53
Study 8101584 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine in 5% dextrose (100 micrograms/kg per h for 2 h followed by 25 micrograms/kg per h continuous infusion)
Number of subjects: 41
Study 8101584 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose (placebo)
Number of subjects: 41
Study 8101584 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 41
Study 8101584 — intervention group
Group type: COMPARATOR
Intervention: Morphine and placebo
Number of subjects: 41
Study 2943812 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of 5 micrograms of hepatitis B recombinant DNA yeast vaccine (H‐B‐VAX II) at 0 and 1 month (Group I)
Number of subjects: 141
Study 2943812 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of 5 micrograms of hepatitis B recombinant DNA yeast vaccine (H‐B‐VAX II) at 0, 1 and 6 months (Group II)
Number of subjects: 141
Study 2943812 — intervention group
Group type: COMPARATOR
Intervention: Three doses of 10 micrograms of plasma‐derived hepatitis B vaccine (H‐B‐VAX) (Group III)
Number of subjects: 141
Study 30253879 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute Onyx stent
Number of subjects: 2488
Study 30253879 — intervention group
Group type: COMPARATOR
Intervention: Orsiro stent
Number of subjects: 2488
Study 25185863 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO) for 5 days
Number of subjects: 43
Study 25185863 — intervention group
Group type: COMPARATOR
Intervention: Non-HFCWO (control)
Number of subjects: 43
Study 24875092 — intervention group
Group type: EXPERIMENTAL
Intervention: Quidel Influenza A+B POCT
Number of subjects: 0
Study 24875092 — intervention group
Group type: COMPARATOR
Intervention: Viral culture
Number of subjects: 0
Study 24875092 — intervention group
Group type: EXPERIMENTAL
Intervention: BinaxNOW pneumococcal POCT
Number of subjects: 0
Study 24875092 — intervention group
Group type: COMPARATOR
Intervention: Sputum culture
Number of subjects: 0
Study 24875092 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall pooled estimates of sensitivity and specificity of POCTs for influenza
Number of subjects: 0
Study 24875092 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR
Number of subjects: 0
Study 24875092 — intervention group
Group type: COMPARATOR
Intervention: Conventional viral culture
Number of subjects: 0
Study 22587925 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin infusion at 18 U×kg(‐1)×h(‐1) for 24 hours (Group A)
Number of subjects: 351
Study 22587925 — intervention group
Group type: COMPARATOR
Intervention: Intravenous drip of 12,500 U of heparin once a day (Group B)
Number of subjects: 351
Study 22587925 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin calcium injection twice a day (Group C)
Number of subjects: 351
Study 20660970 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sodium fluoride iontophoresis
Number of subjects: 30
Study 20660970 — intervention group
Group type: COMPARATOR
Intervention: varnish
Number of subjects: 30
Study 20660970 — intervention group
Group type: COMPARATOR
Intervention: adhesive bonded liner
Number of subjects: 30
Study 18320208 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltodextrin plus hydrolyzed whey protein enriched with 175 mg of glutamine dipeptide (MGln)
Number of subjects: 9
Study 18320208 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 9
Study 15640998 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder ROM assessment (manual measurement)
Number of subjects: 50
Study 15640998 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder ROM assessment (digital analysis)
Number of subjects: 50
Study 15640998 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods of shoulder ROM assessment
Number of subjects: 50
Study 15640998 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of shoulder contractures in patients
Number of subjects: 50
Study 15640998 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of shoulder contractures in all shoulder joints
Number of subjects: 50
Study 12733728 — intervention group
Group type: EXPERIMENTAL
Intervention: Gross motor activities (30 minutes/day, 5 days/week for 12 months) with calcium (1000 mg/day)
Number of subjects: 239
Study 12733728 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine motor activities (30 minutes/day, 5 days/week for 12 months) with calcium (1000 mg/day)
Number of subjects: 239
Study 12733728 — intervention group
Group type: COMPARATOR
Intervention: Gross motor activities (30 minutes/day, 5 days/week for 12 months) with placebo
Number of subjects: 239
Study 12733728 — intervention group
Group type: COMPARATOR
Intervention: Fine motor activities (30 minutes/day, 5 days/week for 12 months) with placebo
Number of subjects: 239
Study 12733728 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1000 mg/day)
Number of subjects: 239
Study 12733728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 10569535 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteroscopy
Number of subjects: 80
Study 10569535 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy
Number of subjects: 80
Study 8939828 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ERC with ESE followed by LC during the same hospital admission (Group A)
Number of subjects: 207
Study 8939828 — intervention group
Group type: COMPARATOR
Intervention: Single stage laparoscopic management (Group B) consisting of LC and laparoscopic stone extraction (trans-cystic duct route or direct supraduodenal common duct exploration)
Number of subjects: 207
Study 1748336 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil, up to 0.025 mg/kg
Number of subjects: 36
Study 1748336 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl, 0.0025 mg/kg
Number of subjects: 36
Study 7019841 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin treatment (0.2 mg/kg enteral indomethacin, three doses at eight-hour intervals in phase 2)
Number of subjects: 39
Study 7019841 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 39
Study 7019841 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin treatment (0.2 mg/kg enteral indomethacin, three doses at 24-hour intervals in phase 1)
Number of subjects: 39
Study 7019841 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin treatment (phase 2)
Number of subjects: 39
Study 30747612 — intervention group
Group type: EXPERIMENTAL
Intervention: Utility-weighted modified Rankin Scale (UW-mRS)
Number of subjects: 2030
Study 30747612 — intervention group
Group type: EXPERIMENTAL
Intervention: AQoL‐4D
Number of subjects: 2030
Study 30747612 — intervention group
Group type: EXPERIMENTAL
Intervention: Time post-stroke
Number of subjects: 2030
Study 30747612 — intervention group
Group type: EXPERIMENTAL
Intervention: Derivation method
Number of subjects: 2030
Study 31533735 — intervention group
Group type: EXPERIMENTAL
Intervention: Support Vector Machine (SVM) algorithm
Number of subjects: 184
Study 26016655 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus CNCM I‐4036
Number of subjects: 0
Study 26016655 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei CNCM I‐4034
Number of subjects: 0
Study 26016655 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve CNCM I‐4035
Number of subjects: 0
Study 24502311 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% methylene blue aqueous solution irradiated with light emission diode device (MBLED/PDT) with 18 J/cm(2) and placebo capsule per week
Number of subjects: 80
Study 24502311 — intervention group
Group type: COMPARATOR
Intervention: 300 mg oral fluconazole per week and placebo PDT (haematoxylin-diluted 1:10)
Number of subjects: 80
Study 23515202 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide 20mg (1ml)
Number of subjects: 188
Study 23515202 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 188
Study 19996072 — intervention group
Group type: EXPERIMENTAL
Intervention: Perihematomal edema growth
Number of subjects: 404
Study 19996072 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hematoma volume
Number of subjects: 404
Study 19996072 — intervention group
Group type: EXPERIMENTAL
Intervention: History of hypertension
Number of subjects: 404
Study 18036291 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion (initial rate 50 microg.kg(‐1).min(‐1) increasing to 150 microg.kg(‐1).min(‐1) over 10 minutes)
Number of subjects: 40
Study 18036291 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline infusion
Number of subjects: 40
Study 14758947 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled regimen of minor oral analgesic medications (acetaminophen [10 mg/kg] and ibuprofen [10 mg/kg] alternating every 2 hours)
Number of subjects: 50
Study 14758947 — intervention group
Group type: COMPARATOR
Intervention: Analgesic medication when requested (Control Group B)
Number of subjects: 50
Study 14758947 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled regimen of minor oral analgesic medications
Number of subjects: 50
Study 11453909 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment group (allergen‐impermeable mattress encasing, acaricide spray containing tannic acid and benzylbenzoate)
Number of subjects: 20
Study 11453909 — intervention group
Group type: COMPARATOR
Intervention: Control group (allergen‐permeable encasing, spray containing water and traces of ethanol)
Number of subjects: 20
Study 11453909 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment group
Number of subjects: 20
Study 11453909 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 9445185 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and etoposide
Number of subjects: 136
Study 9445185 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinomycin
Number of subjects: 136
Study 9445185 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetrexate
Number of subjects: 136
Study 8111718 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC 650 mg/m2
Number of subjects: 63
Study 8111718 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC 850 mg/m2
Number of subjects: 63
Study 8111718 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC (combined low and high doses)
Number of subjects: 63
Study 8111718 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 63
Study 3183054 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine with low-dose naloxone
Number of subjects: 105
Study 3183054 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine with low-dose naloxone
Number of subjects: 105
Study 30755164 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose (11.4 mg betamethasone)
Number of subjects: 3142
Study 30755164 — intervention group
Group type: COMPARATOR
Intervention: Half dose (placebo)
Number of subjects: 3142
Study 28672376 — intervention group
Group type: EXPERIMENTAL
Intervention: Phoneme Factory Sound Sorter software administered by educators over 9 weeks
Number of subjects: 123
Study 28672376 — intervention group
Group type: COMPARATOR
Intervention: Typical classroom practices
Number of subjects: 123
Study 25326216 — intervention group
Group type: EXPERIMENTAL
Intervention: One cycle treatment (group A)
Number of subjects: 409
Study 25326216 — intervention group
Group type: COMPARATOR
Intervention: Two cycle treatment (group B)
Number of subjects: 409
Study 25326216 — intervention group
Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 409
Study 24121100 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (12 weekly group sessions)
Number of subjects: 0
Study 24121100 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention retraining intervention for social anxiety disorder
Number of subjects: 0
Study 24121100 — intervention group
Group type: COMPARATOR
Intervention: Placebo control condition
Number of subjects: 0
Study 21052978 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 9795
Study 21052978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9795
Study 17952446 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 45
Study 17952446 — intervention group
Group type: EXPERIMENTAL
Intervention: Total laparoscopic hysterectomy
Number of subjects: 45
Study 17952446 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 45
Study 17167846 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music (Group 1)
Number of subjects: 60
Study 17167846 — intervention group
Group type: COMPARATOR
Intervention: No music (Group 2)
Number of subjects: 60
Study 14501608 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg E2 + 25 g SPI with 120 mg isoflavones
Number of subjects: 39
Study 14501608 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg E2 + 25 g SPI with 120 mg isoflavones
Number of subjects: 39
Study 14501608 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg E2 + placebo
Number of subjects: 39
Study 14501608 — intervention group
Group type: COMPARATOR
Intervention: 1.0 mg E2 + placebo
Number of subjects: 39
Study 11103750 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclosporine
Number of subjects: 22
Study 11103750 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclosporine
Number of subjects: 22
Study 11103750 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioavailability of cyclosporine
Number of subjects: 22
Study 8730315 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artesunate (100 mg single dose on day 1 followed by 50 mg twice daily for 5 days)
Number of subjects: 40
Study 8730315 — intervention group
Group type: COMPARATOR
Intervention: Oral artemisinin (500 mg single dose on day 1 followed by 250 mg twice daily for 4 days and another 500 mg single dose on day 6)
Number of subjects: 40
Study 1328022 — intervention group
Group type: EXPERIMENTAL
Intervention: Older Alcoholic Rehabilitation (OAR) program
Number of subjects: 137
Study 1328022 — intervention group
Group type: COMPARATOR
Intervention: Traditional care program
Number of subjects: 137
Study 3698064 — intervention group
Group type: EXPERIMENTAL
Intervention: TheoDur
Number of subjects: 13
Study 3698064 — intervention group
Group type: EXPERIMENTAL
Intervention: Respbid
Number of subjects: 13
Study 3698064 — intervention group
Group type: COMPARATOR
Intervention: TheoDur and Respbid
Number of subjects: 13
Study 31215320 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-based learning (CBL)
Number of subjects: 80
Study 31215320 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture-based teaching method
Number of subjects: 80
Study 29194339 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1:1 plasma-platelet-red blood cell ratios
Number of subjects: 454
Study 29194339 — intervention group
Group type: COMPARATOR
Intervention: 1:1:2 plasma-platelet-red blood cell ratios
Number of subjects: 454
Study 26688463 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral herbs (n=35)
Number of subjects: 67
Study 26688463 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (n=32)
Number of subjects: 67
Study 26688463 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-salvage therapy comparison
Number of subjects: 67
Study 24648131 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-procedure ultrasound
Number of subjects: 606
Study 24648131 — intervention group
Group type: COMPARATOR
Intervention: Landmark methods (Pathfinder)
Number of subjects: 606
Study 24648131 — intervention group
Group type: COMPARATOR
Intervention: Landmark methods (Direct Cannulation)
Number of subjects: 606
Study 24648131 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-procedure ultrasound (inexperienced operators)
Number of subjects: 606
Study 24648131 — intervention group
Group type: COMPARATOR
Intervention: Landmark methods (experienced operators)
Number of subjects: 606
Study 22445187 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen group (100% oxygen at 2l/min via nasal cannula for at least 30 min before delivery)
Number of subjects: 56
Study 22445187 — intervention group
Group type: COMPARATOR
Intervention: Room Air group (connected to nasal cannula while on room air)
Number of subjects: 56
Study 20573752 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated A1C (5.7-6.4%)
Number of subjects: 593
Study 20573752 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired Glucose Tolerance (IGT)
Number of subjects: 593
Study 20573752 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired Fasting Glucose (IFG)
Number of subjects: 593
Study 20573752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate and diabetic range of 2-h glucose
Number of subjects: 593
Study 20573752 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic A1C levels in women
Number of subjects: 593
Study 17459139 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation delivered by practice nurses
Number of subjects: 19
Study 15892437 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-drug regimen of indinavir + zidovudine (or stavudine) + lamivudine
Number of subjects: 1178
Study 15892437 — intervention group
Group type: COMPARATOR
Intervention: 2-drug combination of zidovudine (or stavudine) + lamivudine
Number of subjects: 1178
Study 12878621 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 500
Study 10562783 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-free epidural-spinal anaesthesia
Number of subjects: 40
Study 10562783 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia with continuous epidural bupivacaine 15 mg h‐1 or bupivacaine 10 mg h‐1 with epidural morphine 0.2 mg h‐1
Number of subjects: 40
Study 8721469 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSO 50% in a fatty cream (group A)
Number of subjects: 32
Study 8721469 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 32
Study 1676358 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% betaxolol
Number of subjects: 28
Study 1676358 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% metipranolol
Number of subjects: 28
Study 1676358 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol
Number of subjects: 28
Study 1676358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 1676358 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% butylamino-phenoxy-propanol-acetate (BPPA)
Number of subjects: 28
Study 1676358 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% timolol
Number of subjects: 28
Study 6841664 — intervention group
Group type: EXPERIMENTAL
Intervention: Loprazolam (0.5, 1.0, and 1.5 mg)
Number of subjects: 0
Study 6841664 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (10, 20, and 30 mg)
Number of subjects: 0
Study 30753648 — intervention group
Group type: COMPARATOR
Intervention: 5 nights of continuous 6.5-hour time-in-bed (TIB)
Number of subjects: 58
Study 30753648 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hour nocturnal TIB with a 1.5-hour afternoon nap (split sleep)
Number of subjects: 58
Study 30753648 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sleep-restricted groups (split and continuous sleep)
Number of subjects: 58
Study 30413417 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped wedge cluster randomised trial (SW‐CRT)
Number of subjects: 0
Study 30413417 — intervention group
Group type: EXPERIMENTAL
Intervention: CONSORT statements for individual and cluster randomised trials
Number of subjects: 0
Study 30413417 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting items with explanations and examples
Number of subjects: 0
Study 26189570 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular paliperidone palmitate 3-month (PP3M) formulation (75-525 mg eq)
Number of subjects: 328
Study 26189570 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular paliperidone immediate release (IR) (1 mg)
Number of subjects: 328
Study 24263659 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of L-carnitine (LK-3)
Number of subjects: 26
Study 24263659 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g of L-carnitine (LK-4)
Number of subjects: 26
Study 24263659 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P-3 and P-4)
Number of subjects: 26
Study 21820871 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 322
Study 20802094 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 97
Study 20802094 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical treatment
Number of subjects: 97
Study 16714323 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (medium dose: 115 microg/kg)
Number of subjects: 12
Study 16714323 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (high dose: 250 microg/kg)
Number of subjects: 12
Study 16714323 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (medium and high doses)
Number of subjects: 12
Study 16714323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15288990 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron (12.5 mg)
Number of subjects: 304
Study 15288990 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (10 microg. kg(‐1))
Number of subjects: 304
Study 15288990 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of droperidol and dolasetron
Number of subjects: 304
Study 15288990 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 304
Study 11751803 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telemedicine unit providing synchronous videoconferencing with a project-based nurse, electronic transmission of home fingerstick glucose and blood pressure data, and Web access to a project Web site.
Number of subjects: 1500
Study 11751803 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract).
Number of subjects: 1500